Platelet-Activating Factor Receptor (PTAFR) Antibody (FITC)
169€ (20 µg)
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
935106861
info@markelab.com
name
Platelet-Activating Factor Receptor (PTAFR) Antibody (FITC)
category
Primary Antibodies
provider
Abbexa
reference
abx304997
Description
PTAFR Antibody (FITC) is a Rabbit Polyclonal against PTAFR conjugated to FITC.
Documents del producto
Instrucciones
Data sheet
Product specifications
| Category | Primary Antibodies |
| Immunogen Target | Platelet-Activating Factor Receptor (PTAFR) |
| Host | Rabbit |
| Reactivity | Human |
| Recommended Dilution | Optimal dilutions/concentrations should be determined by the end user. |
| Clonality | Polyclonal |
| Conjugation | FITC |
| Isotype | IgG |
| Purity | > 95% |
| Purification | Purified by Protein G. |
| Size 1 | 20 µg |
| Size 2 | 50 µg |
| Size 3 | 100 µg |
| Size 4 | 200 µg |
| Size 5 | 1 mg |
| Form | Liquid |
| Buffer | 0.01 M PBS, pH 7.4, 0.03% Proclin-300 and 50% Glycerol. |
| Availability | Shipped within 5-10 working days. |
| Storage | Aliquot and store at -20°C. Avoid exposure to light. Avoid repeated freeze/thaw cycles. |
| Dry Ice | No |
| UniProt ID | P25105 |
| Gene ID | 5724 |
| OMIM | 173393 |
| Alias | PTAFR,PAFr,AGEPC receptor |
| Background | Antibody anti-PTAFR |
| Status | RUO |
Descripción
PTAFR is a G protein-coupled receptor activated by platelet-activating factor (PAF), a potent phospholipid mediator involved in inflammation, immune responses, and thrombosis. PTAFR is widely expressed on platelets, endothelial cells, leukocytes, and in various tissues, where it mediates diverse inflammatory and immune responses. Upon activation, PTAFR couples to Gq and Gi proteins, leading to calcium mobilization, activation of phospholipase C (PLC), and downstream signaling pathways that promote chemotaxis, cytokine release, and oxidative stress. PTAFR plays a central role in allergic reactions, asthma, cardiovascular dysfunction, and sepsis by amplifying inflammatory cascades and vascular permeability. Dysregulation of PTAFR is associated with chronic inflammatory diseases, ischemic injuries, and immune-related conditions. PTAFR antagonists are being explored as potential therapeutics for asthma, sepsis, and cardiovascular diseases by suppressing excessive PAF-mediated inflammation and thrombosis. Its involvement in inflammation and vascular responses positions PTAFR as a critical target for treating immune and inflammatory disorders.
Related Products
PTAFR antibody
Receptor for platelet activating factor, a chemotactic phospholipid mediator that possesses potent inflammatory, smooth-muscle contractile and hypotensive activity. Seems to mediate its action via a G protein that activates a phosphatidylinositol-calcium second messenger system.
Ver Producto
Platelet-Activating Factor Receptor (PTAFR) Antibody
PTAFR Antibody is a Rabbit Polyclonal against PTAFR.
Ver Producto
Platelet-Activating Factor Receptor (PTAFR) Antibody (HRP)
PTAFR Antibody (HRP) is a Rabbit Polyclonal against PTAFR conjugated to HRP.
Ver Producto